E.V.O.L.V.E. Trial™: EValuation Of Cinacalcet Hydrochloride (HCl) Therapy to Lower CardioVascular Events
Status:
Completed
Trial end date:
2012-04-10
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effects of cinacalcet (cinacalcet HCl or
Sensipar®/Mimpara®) on cardiovascular events and death in chronic kidney disease (CKD)
patients with secondary hyperparathyroidism (HPT) who are receiving dialysis.